| CRDF |
Cardiff Oncology, Inc. |
72%
|
oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem… |
| CRDF |
Cardiff Oncology, Inc. |
72%
|
Reciprocal relationship from CRDF graph: Reciprocal relationship from OKYO graph: oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates… |
| HEPA |
Hepion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from HEPA graph: Reciprocal relationship from OKYO graph: oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates… |
| HEPA |
Hepion Pharmaceuticals, Inc. |
72%
|
oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem… |
| IMRN |
Immuron Limited |
72%
|
oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem… |
| IMRN |
Immuron Limited |
72%
|
Reciprocal relationship from IMRN graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from IMRN graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from IMRN g… |
| SIGA |
SIGA Technologies, Inc. |
72%
|
oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem… |
| SIGA |
SIGA Technologies, Inc. |
72%
|
Reciprocal relationship from SIGA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from SIGA graph: Reciprocal relationship from OKYO graph: oreign currency transactions are tr… |
| TLSA |
Tiziana Life Sciences Ltd |
72%
|
Reciprocal relationship from TLSA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA g… |
| TLSA |
Tiziana Life Sciences Ltd |
72%
|
Group ordinarily finances its activities through cash generated from by private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group’s fina… |
| ALPHA-GROUP |
ALPHA-GROUP |
62%
|
Group ordinarily finances its activities through cash generated from by private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group’s fina… |
| BRITISH-VIRGIN-ISLANDS-BUSINESS-COMPANY |
BRITISH-VIRGIN-ISLANDS-BUSINESS-COMPANY |
62%
|
tions of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider. Any of the… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates or any future product candidates and to conduct clinical trials, and similar e… |
| LEASES-THE-GROUP |
LEASES-THE-GROUP |
62%
|
consistent with that presented elsewhere. SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS Year ended March 31, 2024 2023 (Loss) attributable to equity holde… |
| OKYO-PHARMA-LTD |
OKYO-PHARMA-LTD |
62%
|
y with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient information and reporting cybersecurity incidents to the SEC… |
| OKYO-PHARMA-US-INC |
OKYO-PHARMA-US-INC |
62%
|
party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of the Company’s product candidates, once approved… |
| ON-TARGET-THERAPEUTICS-LLC |
ON-TARGET-THERAPEUTICS-LLC |
62%
|
y with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient information and reporting cybersecurity incidents to the SEC… |
| REPORTING-ENTITY-OKYO-PHARMA-LIMITED |
REPORTING-ENTITY-OKYO-PHARMA-LIMITED |
62%
|
y with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient information and reporting cybersecurity incidents to the SEC… |
| TIZIANA-LIFE-SCIENCES-LIMITED |
TIZIANA-LIFE-SCIENCES-LIMITED |
62%
|
oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem… |
| TIZIANA-LIFE-SCIENCES-LTD-TIZIANA-LIFE-SCIENCES- |
TIZIANA-LIFE-SCIENCES-LTD-TIZIANA-LIFE-SCIENCES- |
62%
|
Group ordinarily finances its activities through cash generated from by private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group’s fina… |
| TUFTS-MEDICAL-CENTER-INC |
TUFTS-MEDICAL-CENTER-INC |
62%
|
y with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient information and reporting cybersecurity incidents to the SEC… |
